|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.50 GBX | 0.00% |
|
0.00% | -20.41% |
| Jan. 10 | Arecor Therapeutics shares tumble as plans Tetris wind-down | AN |
| Jan. 10 | Arecor Therapeutics to Shutter Tetris Pharma Unit; Ends License Deal with Xeris | MT |
| Capitalization | 22.09M 27.25M 26.18M 24.75M 39.18M 2.36B 43.41M 300M 110M 971M 102M 100M 4.25B | P/E ratio 2024 * |
-1.95x | P/E ratio 2025 * | -2.93x |
|---|---|---|---|---|---|
| Enterprise value | 18.76M 23.15M 22.23M 21.02M 33.28M 2B 36.87M 255M 93.74M 825M 86.8M 85.03M 3.61B | EV / Sales 2024 * |
3.43x | EV / Sales 2025 * | 3.53x |
| Free-Float |
58.34% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Arecor Therapeutics plc
More press releases
| Current month | -20.41% | ||
| 1 month | -15.83% | ||
| 3 months | -20.95% | ||
| 6 months | -36.76% | ||
| Current year | -20.41% |
1 week
57.50
60.00
1 month
54.7575.00
Current year
54.7575.00
1 year
54.75170.00
3 years
54.75435.00
5 years
54.75472.00
10 years
54.75472.00
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 50 | 2021-04-12 |
David J. Ellam
DFI | Director of Finance/CFO | - | 2024-11-17 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 2007-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Smith
BRD | Director/Board Member | 79 | 2021-04-12 |
Sarah Howell
BRD | Director/Board Member | 50 | 2021-04-12 |
Mohammad Fazeli
BRD | Director/Board Member | 60 | 2017-08-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -65.07% | -84.81% | 27.25M | ||
| +0.48% | +6.46% | +56.06% | -9.22% | 46.39B | ||
| +0.28% | +4.22% | -3.53% | -14.51% | 37.39B | ||
| -0.78% | -1.59% | +3.55% | +19.62% | 26.47B | ||
| -0.19% | +0.10% | -23.22% | -19.56% | 16.73B | ||
| +0.16% | +1.50% | +70.76% | +85.89% | 16.6B | ||
| +10.10% | +25.56% | -58.41% | -73.52% | 16.31B | ||
| -2.29% | +1.06% | +6.11% | -16.20% | 12.22B | ||
| +0.79% | +3.29% | +16.35% | +111.13% | 10.79B | ||
| -3.01% | -0.15% | +0.03% | -8.70% | 10.19B | ||
| Average | -0.18% | +4.15% | +0.26% | -0.99% | 19.31B | |
| Weighted average by Cap. | +0.03% | +4.84% | +13.70% | +1.86% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 5.46M 6.74M 6.47M 6.12M 9.69M 583M 10.74M 74.25M 27.3M 240M 25.27M 24.76M 1.05B | 6.2M 7.64M 7.34M 6.94M 10.99M 661M 12.18M 84.21M 30.96M 272M 28.66M 28.08M 1.19B |
| Net income | -8.03M -9.91M -9.52M -9M -14.25M -857M -15.78M -109M -40.13M -353M -37.16M -36.4M -1.55B | -6.18M -7.62M -7.32M -6.92M -10.96M -659M -12.14M -83.99M -30.87M -272M -28.59M -28.01M -1.19B |
| Net Debt | -3.33M -4.11M -3.94M -3.73M -5.9M -355M -6.54M -45.22M -16.62M -146M -15.39M -15.08M -640M | -199K -246K -236K -223K -354K -21.26M -392K -2.71M -996K -8.77M -922K -903K -38.36M |
More financial data
* Estimated data
Employees
50
Calendar
2025-04-27
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-23 | 58.50 p | 0.00% | 150 |
| 25-01-22 | 58.50 p | 0.00% | 1,315 |
| 25-01-21 | 58.50 p | 0.00% | 20,712 |
| 25-01-20 | 58.50 p | 0.00% | 600 |
| 25-01-17 | 58.50 p | 0.00% | 985 |
Delayed Quote London S.E., January 23, 2025 at 11:35 am EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.5850GBP
Average target price
3.257GBP
Spread / Average Target
+456.70%
Annual profits - Rate of surprise
- Stock Market
- Equities
- AREC Stock